The Unknown Puts Offspring At Risk Of Sickle Cell Disease
Most Connecticut residents who carry a trait for sickle cell disease don’t know it, resulting in thousands of people unwittingly risking having a child born with the debilitating illness, according to sickle cell disease specialists.Source: CT News Junkie
Yale Researchers Explore Mindfulness-Based Treatments to Address Chronic Pain and Improve Health Outcomes in Individuals with Sickle Cell Disease
For individuals with Sickle Cell Disease (SCD), pain can be a pervasive aspect of everyday life, affecting both physical and mental health. An ongoing study in collaboration with the Yale Sickle Cell Program is set to examine the efficacy of mindfulness-based treatments (MBT) to address pain and improve quality of life for SCD patients. Led by Zachary Harvanek, MD, PhD, John Roberts, MD, Ariadna Forray, MD, and Michael Crowley, PhD, “Neural Correlates of Pain, Resiliency, and Mindfulness in Patients with Sickle Cell Disease” will explore neural markers of chronic pain in patients with SCD and assess whether MBT can improve both chronic pain and SCD in this population.
How Studying Cellular Senescence Can Help Researchers Learn to Delay Aging
Chronic inflammation, one of the major hallmarks of aging, is thought to be partly caused by senescent cells that may accumulate in older individuals. Now, Yale researchers have received a grant from the National Institutes of Health (NIH) Common Fund’s Cellular Senescence Network Program (SenNet) to study these specialized cells.
Yale Cancer Center Diversity Enhancement Program in Oncology welcomes first students
The Diversity Enhancement Program in Oncology program offers an eight-week rotation for two underrepresented in medicine (URiM) students or residents, and is designed to provide exposure to hematology/medical oncology as a career, provide faculty-mentored clinical experience in oncology as well as with a corresponding clinical or translational research project. Students also receive co-mentorship from current Medical Oncology-Hematology T32 fellows.